Log in

TSE:PMN - Promis Neurosciences Stock Price, Forecast & News

0.00 (0.00 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
Now: C$0.14
50-Day Range
MA: C$0.19
52-Week Range
Now: C$0.14
Volume137,796 shs
Average Volume248,598 shs
Market CapitalizationC$39.44 million
P/E RatioN/A
Dividend YieldN/A
ProMIS Neurosciences, Inc., a development stage biotech company, discovers and develops precision medicine therapeutics for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson's disease (PD). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform—ProMIS and Collective Coordinates to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb); PMN350, a mAb targeting on toxic amyloid beta oligomers (AßO); and PMN330, a monoclonal antibody targeting toxic prionlike forms of AßO for AD. The company is also developing therapeutics targeting the neurotoxic form of the tau protein in AD; and superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in PD and Lewy body dementia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Read More

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual SalesC$475.00
Price / Sales83,026.78
Cash FlowC$0.00 per share
Book ValueC$0.00 per share



Market CapC$39.44 million
Next Earnings Date5/12/2020 (Estimated)
OptionableNot Optionable

Receive PMN News and Ratings via Email

Sign-up to receive the latest news and ratings for PMN and its competitors with MarketBeat's FREE daily newsletter.

Promis Neurosciences (TSE:PMN) Frequently Asked Questions

How has Promis Neurosciences' stock been impacted by COVID-19 (Coronavirus)?

Promis Neurosciences' stock was trading at C$0.18 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PMN stock has decreased by 22.2% and is now trading at C$0.14. View which stocks have been mosted impacted by Coronavirus.

When is Promis Neurosciences' next earnings date?

Promis Neurosciences is scheduled to release its next quarterly earnings announcement on Tuesday, May 12th 2020. View our earnings forecast for Promis Neurosciences.

Has Promis Neurosciences been receiving favorable news coverage?

Headlines about PMN stock have been trending very positive this week, InfoTrie reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Promis Neurosciences earned a daily sentiment score of 4.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutPromis Neurosciences.

Who are some of Promis Neurosciences' key competitors?

What other stocks do shareholders of Promis Neurosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Promis Neurosciences investors own include Crispr Therapeutics (CRSP), Keurig Dr Pepper (KDP), Aurora Cannabis (ACB), Spectra7 Microsystems (SEV), NVIDIA (NVDA), Flexion Therapeutics (FLXN), Onconova Therapeutics (ONTX), QUALCOMM (QCOM), Advanced Micro Devices (AMD) and Editas Medicine (EDIT).

Who are Promis Neurosciences' key executives?

Promis Neurosciences' management team includes the following people:
  • Mr. Eugene Williams, Exec. Chairman (Age 60)
  • Dr. Elliot Goldstein, Pres, CEO & Director (Age 68)
  • Dr. Neil R. Cashman, Founder, Chairman of Scientific Advisory Board, Chief Scientific Officer & Director
  • Mr. Daniel E. Geffken, Chief Financial Officer (Age 62)
  • Dr. Johanne Kaplan, Chief Devel. Officer

What is Promis Neurosciences' stock symbol?

Promis Neurosciences trades on the Toronto Stock Exchange (TSX) under the ticker symbol "PMN."

How do I buy shares of Promis Neurosciences?

Shares of PMN and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Promis Neurosciences' stock price today?

One share of PMN stock can currently be purchased for approximately C$0.14.

How big of a company is Promis Neurosciences?

Promis Neurosciences has a market capitalization of C$39.44 million and generates C$475.00 in revenue each year.  View additional information about Promis Neurosciences.

What is Promis Neurosciences' official website?

The official website for Promis Neurosciences is http://www.amorfix.com/.

How can I contact Promis Neurosciences?

Promis Neurosciences' mailing address is 1920 Yonge St Suite 200, TORONTO, ON M4S 3E2, Canada. The company can be reached via phone at +1-416-8476898.

MarketBeat Community Rating for Promis Neurosciences (TSE PMN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  194 (Vote Outperform)
Underperform Votes:  161 (Vote Underperform)
Total Votes:  355
MarketBeat's community ratings are surveys of what our community members think about Promis Neurosciences and other stocks. Vote "Outperform" if you believe PMN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PMN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Featured Article: What is the LIBOR?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel